Interaction Network Design for the Target Assessment of Clinically Significant Drugs Repurposed Against the COVID-19 Disease

Iqra Noor

Reg No. 00000317874

Master of Science in Industrial Biotechnology

Supervisor

Dr. Saadia Andleeb

Department of Industrial Biotechnology

Atta-Ur-Rahman School of Applied Biosciences (ASAB)

National University of Sciences and Technology (NUST)

Islamabad, Pakistan

2021

Interaction Network Design for the Target Assessment of Clinically Significant Drugs Repurposed Against the COVID-19 Disease

A thesis submitted in partial fulfilment of the requirement for the degree of

Master of Science

In

Industrial Biotechnology

By

Iqra Noor

Registration No. 00000317874

Supervised by

Dr. Saadia Andleeb

Department of Industrial Biotechnology
Atta-Ur-Rahman School of Applied Biosciences (ASAB)
National University of Sciences and Technology (NUST)
H-12, Islamabad, Pakistan

2021

THESIS ACCEPTANCE CERTIFICATE

Certified that the contents and form of MS/MPhil thesis entitled **"Interaction Network Design for the Target Assessment of Clinically Significant Drugs Repurposed Against the COVID-19 Disease"** written by Ms. Iqra Noor**,** Registration No. 00000317874, of Atta-ur-Rahman School of Applied Biosciences has been vetted by the undersigned, found complete in all respects as per NUST statutes/ regulations, is free of plagiarism, errors and mistakes and is accepted as partial fulfillment for award of MS/MPhil Degree. It is further certified that necessary amendments as pointed out by GEC members of the scholar have also been incorporated in the said thesis, have been found satisfactory for the requirement of the degree.

Supervisor: _____

Dr. Saadia Andleeb

ASAB, NUST

Head of Department: _____

Dr. Saadia Andleeb

ASAB, NUST

Principal:_____

Dr. Hussnain Ahmed Janjua

ASAB, NUST

DECLARATION

I, **Iqra Noor**, declare that this research work entitled **"Interaction Network Design for the Target Assessment of Clinically Significant Drugs Repurposed Against the COVID-19 Disease"** is my own work. The work has not been presented elsewhere for assessment. The work here in was carried out while I was a post-graduate student at Atta-ur-Rahman School of Applied Biosciences, NUST under the supervision of Dr. Saadia Andleeb. The material that has been used from other sources has been properly acknowledged / referred.

_____

Iqra Noor

Master of Science

Industrial Biotechnology

Reg No: 00000317874

CERTIFICATE FOR PLAGIARISM

It is confirmed that MS Thesis entitled **"Interaction Network Design for the Target Assessment of Clinically Significant Drugs Repurposed Against the COVID-19 Disease"** of Ms. Iqra Noor, Reg No. 00000317874 has been examined by me. I undertake that:

a. Thesis has significant new work/knowledge as compared to already published or are under consideration to be published elsewhere. No sentence, equation, diagram, table, paragraph, or section has been copied verbatim from previous work unless it is placed under quotation marks and duly referenced.
b. The work presented is original and own work of the author (i.e., there is no plagiarism). No ideas, processes, results, or words of others have been presented as author's own work.
c. There is no fabrication of data or results that the research is not accurately represented in the records. The thesis has been checked using TURNITIN (a copy of the originality report attached) and found within limits as per HEC plagiarism Policy and instructions issued from time to time.

_____

(Supervisor)

Dr. Saadia Andleeb

(Head of Department, ASAB, NUST)

Dedicated to

All the kind souls that restore my faith in humanity

ACKNOWLEDGEMENTS

In the name of **Allah**, the most beneficent and the most merciful. All praises to Almighty Allah for giving me opportunity, determination, and strength to do my research and thesis.

I would like to express my deepest gratitude to my supervisor, **Dr. Saadia Andleeb**, whose sincerity and encouragement I will never forget. Dr. Saadia has been an inspiration as I hurdled through the path of this Master's degree. She is the true definition of a leader and the ultimate role model. This thesis would not have been possible without Dr. Saadia, whose guidance from the initial step in research enabled me to develop an understanding of the subject. I am thankful for the extraordinary experiences she arranged for me and for providing opportunities for me to grow professionally. It has been an honor to learn from Dr. Saadia Andleeb.

Thank you to my GEC members, **Dr. Abdur Rahman**, **Dr. Najam us Sahar Sadaf Zaidi**, and external examiner **Dr. Bashir Ahmad**. Their encouraging words and thoughtful, detailed feedback have been very important to me. I am also thankful to **Dr. Hussnain Ahmed Janjua**, Principal ASAB NUST for his valuable guidelines and facilitation.

For every achievement in life, I always must share the credit with one person and that is my **Mother**, she is my comfort place. Also, I am grateful for my parents, **Dilshad Zaheer** and **Sardar Zaheer Mohabbat (Late)**, whose constant love and support keep me motivated and confident. My accomplishments and success are because they believed in me. You have always stood behind me, and this was no exception. Thank you to my siblings, **Hifza Noor**, **Isbah Noor**, and **Mohammad Arslan Zaheer** for your endless support.

Deepest thanks to my best friends, **Ayesha Rafique** and **Hayeqa Shahwar Awan** who keep me grounded, remind me of what is important in life, and are always supportive of my adventures. I have been blessed to have come across some amazing people in my life. I would like to thank my senior **Sidra Irum** who has been such a moral support and gave me a sense of motivation to keep going every time I would fall short of it. Life would not have been fun without the wittiness of my friends, **Aeraj Amjad**, **Ayesha Gul**, and **Hafsa Raja**. They lightened up my mood after every encounter of stress. Thank you to my friends, **Shabana Gul**, **Saba Talib**, **Shaheer Shafiq**, **Afraz Saeed**, and **Mohammad Nauman Sharif**. My gratitude to my special friend **Tehreem Nadeem** for being such a sweet friend. I cannot forget to thank my amazing friend **Andleeb Khizar** who has grown really close to my heart in such a limited time.

My sincerest thanks to my lab fellows **Aeraj Amjad**, **Mariam Mumtaz**, **Maryam Shahid**, **Andleeb Khizar**, **Bakhtawar Nawaz**, **Sadia Masood**, **Saba Jahan**, and **Nauman Khaliq** for being supportive and cooperative throughout my research. Thank you to each and every one of my friends for remaining true to me.

Iqra Noor

Table of Contents

ABSTRACT.....Error! Bookmark not defined.

CHAPTER 1

INTRODUCTION.....Error! Bookmark not defined.

1.1. Drug Molecules and Drug Targets Active against the COVID-19 Disease 5

1.2. Research Objectives 7

CHAPTER 2

LITERATURE REVIEW **9**

2.1. Overview of SARS-CoV-2 9

2.2. Evolutionary History of SARS-CoV-2 12

2.3. Development of Immune Response and the COVID-19 disease progression 14

2.4. Disease Transmission and Clinical Manifestations 16

2.5. Diagnosis 18

2.6. Precautionary Measures to Reduce Disease Severity and Tranmission 20

2.7. Clinical Role of Secondary Infections in the COVID-19 Disease 20

2.8. Review of Experimental Treatments 23

2.9. COVID-19 Vaccines: The Bright Side of Human Creativity 24

2.9.1. Mutation Mechanisms of SARS-CoV-2: Global Challenge for the Bright Side of Human Creativity 24

CHAPTER 3

MATERIALS AND METHODS **28**

3.1. Study Design and Data Collection 28

3.1.1. Screening of Repurposable Drug Candidates (DrugBank) 28

3.1.2. Drug-Gene Interaction Study (Drug Gene Interaction Database) 28

3.1.3. Gene-Gene Interaction Study and Network Construction (GeneMANIA and Cytoscape) 28

3.1.4. Layout Adjustment of Drug-Gene-Gene Interaction Networks (Cytoscape) 28

3.1.5. Network-based Enrichment Analysis (EnrichNet) 28

3.1.6. Comparative Analysis (Target Assessment of Drugs) 28

3.2. Access to the Software 29

3.2.1. DrugBank Database 29
3.2.2. Drug Gene Interaction Database 29
3.2.3. GeneMANIA 29
3.2.4. Cytoscape 29
3.2.5. EnrichNet 29
3.3. EnrichNet RWR Relevance Scoring 29
3.3.1. Random Walk With Restart (RWR) Approach 30
3.3.2. Pathway-based Background Model 30

CHAPTER 4

RESULTS 32

4.1. Selection of Repurposable Drug Candiadtes (DrugBank Database) 32
4.2. Identification of Druggable Genes (DGIdb) 32
4.3. Construction of Gene-Gene Interaction Networks (GeneMANIA and Cytoscape, Network 1-17) 32
4.4. Removal of Duplicated Edges and Layout Selection (Cytoscape, Network 1-17) 33
4.5. Drug-pathway Interaction Study and Network-based Enichment Analysis (EnrichNet) 33
4.6. Comparative Analysis of Gene-sets and Pathways for Target Assessment of Categorised Drugs 34
4.6.1. Clinically Significant Genes and Drug-Target Interactions 35
4.6.2. Clinically Significant Pathways and Drug-Target Interactions 35

CHAPTER 5

DISCUSSION 38

CHAPTER 6

CONCLUSION 44

CHAPTER 7

FUTURE PERSPECTIVE 46

(Chapter 4. Results Compilation Pg. 47-90)

CHAPTER 8

REFERENCES 91

List of Figures

Figure 1: Drug targets uncovered for the COVID-19 disease management 6

Figure 2: The structural proteins of SARS-CoV-2 9

Figure 3: The genomic distribution of SARS-CoV-2 proteins 10

Figure 4 (a) (b): The trimeric structure and key features of the spike protein 11

Figure 5 (a) (b) (c): Cellular mechanism of virus attachement and subsequent internalization 12

Figure 6A: SARS-CoV-2 nucleotide sequence identity to SARS-CoV and MERS-CoV 13

Figure 6B: Categorization of the genetically distinct coronaviruses 13

Figure 7: The COVID-19 disease timeline 14

Figure 8: The infectious phases and complications associated with the COVID-19 disease progression 14

Figure 9: Immune response development in the COVID-19 disease 15

Figure 10: Innate immune response during the COVID-19 disease progression 16

Figure 11: Adaptive immune response during the COVID-19 disease progression 16

Figure 12: Fomites act as a significant route for viral transmission 17

Figure 13: Clinical case definitions for the COVID-19 disease 20

Figure 14: Classification of co-infections based on the procalcitonin blood test 22

Figure 15: Mechanisms of co-infection stimulated by the pathogenic microorganisms 22

Figure 16: Types of vaccines designed to instruct immune response development during the COVID-19 disease progression 24

Figure 17: Study design for the network-based analysis of repurposable drug categories. .. 28

Figure 18: Structures of the repurposable drug candidates retrieved from the DrugBank database..... 32, 53-57

Figure 19: The SARS-CoV-connected gene modules reviewed from the human interactome studies 34

Figure 20: Interaction of repurposable drug candidates with clinically significant genes 35

Figure 21: Interaction of repurposable drug candidates with clinically significant pathways 36

List of Interaction Networks

Network 1: Interaction network for the drug **TOCILIZUMAB**..... 59

Network 2: Interaction network for the drug **REMDESIVIR**..... 59

Network 3: Interaction network for the drug **DEXAMETHASONE**..... 60

Network 4: Interaction network for the drug **BARICITINIB**..... 60

Network 5: Interaction network for the drug **RITONAVIR**..... 61

Network 6: Interaction network for the drug **DARUNAVIR**..... 61

Network 7: Interaction network for the drug **COLCHICINE**..... 62

Network 8: Interaction network for the drug **HUMAN INTERFERON BETA**..... 62

Network 9: Interaction network for the drug **UMIFENOVIR**..... 63

Network 10: Interaction network for the drug **LERONLIMAB**..... 63

Network 11: Interaction network for the drug **METHYLPREDNISOLONE**..... 64

Network 12: Interaction network for the drug **SARILUMAB**..... 64

Network 13: Interaction network for the drug **ELBASVIR**..... 65

Network 14: Interaction network for the drug **IBUPROFEN**..... 65

Network 15: Interaction network for the drug **IFENPRODIL**..... 66

Network 16: Interaction network for the drug **ABIVERTINIB**..... 66

Network 17: Interaction network for the drug **FOSTAMATINIB**..... 67

List of Tables

Table 1: Systematic presentation of the transmission routes of closely linked respiratory coronaviruses 12

Table 2 (a) (b): Factors affecting the COVID-19 disease transmission 17

Table 3: Symptoms of the COVID-19 disease 18

Table 4: Diagnostic procedures and criteria for the COVID-19 disease detection 19

Table 5: Classification of respiratory pathogens stimulating co-infections alongside the COVID-19 disease……..21

Table 6: Prospective drug categories to repurpose against the COVID-19 disease 23

Table 7: Mutation mechanisms and viral variants that challenge the test design and diagnostic criteria for the COVID-19 disease therapy 25

Table 8: Currently specified mutations of interest reported in different variants of the severe acute respiratory syndrome coronavirus 2……..26

Table 9 (A): Description and categories of drug candidates repurposed against the COVID-19 disease……47

Table 9 (B): Reported adverse effects of repurposable drug candidates……50

Table 10: Data of repurposable drug candidates listed with accession number, type, groups, and chemical formulae……...51

Table 11: Drug-gene interaction data of filtered drug candidates sourced from DGIdb…….....58

Table 12: Gene-gene interaction data of filtered drug candidates sourced from GeneMANIA and Cytoscape…….....68

Table 13: Drug-pathway interaction with significant network distribution scores sourced from EnrciNet. The distribution scores represent drugs that are more likely to interact with their specified pathways.....74
Table 14: Enrichment analysis of repurposable drug candidates sourced from EnrichNet …….....76

List of Abbreviations

PECAM1 - Platelet Endothelial Cell Adhesion Molecule

GAB1 - GRB2 Associated Binding Protein1

TIE2 - Angiopoeitin-1 Receptor

NICD - Notch1 Intracellular Domain

TAT - Trans-Activator of Transcription

AMPK - AMP-Activated Protein Kinase

TLR4 - Toll-Like Receptor 4

AP1 - Activating Protein 1

CD28 - Cluster of Differentiation 28

VAV1 - Vav Guanine Nucleotide Exchange Factor 1

SOS - Son of Sevenless - Guanine Nucleotide Exchange Factor

PI3K - Phosphoinositide 3-Kinases

AKT - Protein Kinase B

FGFR - Fibroblast Growth Factor Receptor

CCT TRIC - Chaperonin containing Tailless Complex Polypeptide 1 or Tailless Complex Polypeptide 1 Ring Complex

NUMA - Protein of the Nucleus and Mitotic Apparatus

MTOC - Microtubule Organizing Center

JAKs - Janus Kinases

STATs - Signal Transducer and Activator of Transcription Proteins

ERK1/2 - Extracellular Signal-Regulated Kinases

CCR - CC-Chemokine Receptor-1

GTPases - GTP-Binding Proteins

HIV - Human Immunodeficiency Virus

ZAP70 - Zeta-Associated Protein 70

G ALPHA I - Gi Protein Alpha Subunit

CTLA4 - Cytotoxic T-Lymphocyte-Associated Protein 4

BH3 only proteins - Bcl2 Homology 3 (pro-apoptotic member of the Bcl-2 protein family)

SUMO - Small Ubiquitin-Related Modifier

UDP - Uridine 5'-Diphospho Glucuronosyltransferase (UGT)

NSAID - Nonsteroidal Anti-inflammatory Drug

COX - Cyclooxygenase

TOR - Target of Rapamycin

G1/S phase - G1 (GAP 1 - Cell Growth), S (Synthesis of DNA)

MTORC1 - MTOR Complex 1

MTOR - Mammalian Target of Rapamycin

ERBB - The Epidermal Growth Factor Receptor Family (EGFR) of Receptor Tyrosine Kinases (RTKs)

Fc Receptor - Fragment Crystallizable

Ras - Rat Sarcoma

Rho - Ras Homologous (Ras superfamily of small GTPases)

PD1 - Programmed Cell Death Protein 1

SYK - Spleen Tyrosine Kinase

NS5A - Nonstructural Protein 5A

HIF-1 - Hypoxia-inducible Factor 1